Abstract
This is to review current clinical and experimental studies giving data about safety and efficacy of cerebrolysin (cere) in the therapy of mental and neurological disorders. Cere is a mixture of peptides and aminoacids of animal origin, which is used in the therapy of organic, metabolic and neurodegenerative brain diseases. Cere shows neurotrophic activity, which results from it's neuroprotective and neuroregenerative effects. Presented clinical studies concern Alzheimer disease (AD), vascular dementia (VaD), stroke, traumatic brain injury (TBI), and two studies containing small groups of patients with Asperger syndrome, childhood autism and progressive supranuclear palsy. Here presented experimental studies suggest possible mechanisms of the drug's action.